A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders

Monojit Das; Susmita Mondal; Ria Ghosh; Pritam Biswas; Ziad Moussa; Soumendra Darbar; Saleh A. Ahmed; Anjan Kumar Das; Siddhartha Sankar Bhattacharya; Debasish Pal; Asim Kumar Mallick; Prantar Chakrabarti; Jayanta Kumar Kundu; Aniruddha Adhikari; Samir Kumar Pal

doi:10.1016/j.isci.2022.105021

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders

Monojit Das, Susmita Mondal, Ria Ghosh, Pritam Biswas, Ziad Moussa, Soumendra Darbar, Saleh A. Ahmed, Anjan Kumar Das, Siddhartha Sankar Bhattacharya, Debasish Pal, Asim Kumar Mallick, Prantar Chakrabarti, Jayanta Kumar Kundu, Aniruddha Adhikari, Samir Kumar Pal

Department of Chemistry

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

The usual treatment for anemia and especially for anemia of inflammation (also called anemia of chronic disease) is supportive care with the target of improving the lifestyle of the patients. There is no effective medication to date for proper management. As the inflammation, erythropoiesis, and oxidative stress are the major concerns in this case, it inspired us to use a nano-erythropoietin stimulating agent (nano-ESA) made up of a nano-complex of manganese and citrate (Mn-citrate nano-complex), which has been hypothesized to have excellent antioxidant and anti-inflammatory mechanisms. Single oral dose of the nano-ESA efficiently prevented the onset of anemia as well as led to recovery from anemia in our phenylhydrazine (PHz)-intoxicated C57BL/6J mice model of anemia without any toxicological side effects. These preliminary findings may pave the way for an affordable and safe clinical use of the nano-ESA as a rapid recovery medication of anemia, especially anemia of inflammation.

Original language	English
Article number	105021
Journal	iScience
Volume	25
Issue number	9
DOIs	https://doi.org/10.1016/j.isci.2022.105021
Publication status	Published - Sept 16 2022

Keywords

Medical biochemistry
Molecular medicine
Nanotechnology

ASJC Scopus subject areas

General

Access to Document

10.1016/j.isci.2022.105021

Cite this

Das, M., Mondal, S., Ghosh, R., Biswas, P., Moussa, Z., Darbar, S., Ahmed, S. A., Das, A. K., Bhattacharya, S. S., Pal, D., Mallick, A. K., Chakrabarti, P., Kundu, J. K., Adhikari, A., & Pal, S. K. (2022). A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders. iScience, 25(9), Article 105021. https://doi.org/10.1016/j.isci.2022.105021

@article{eafccfd48713457aba99dc0a1a63e5a2,

title = "A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders",

abstract = "The usual treatment for anemia and especially for anemia of inflammation (also called anemia of chronic disease) is supportive care with the target of improving the lifestyle of the patients. There is no effective medication to date for proper management. As the inflammation, erythropoiesis, and oxidative stress are the major concerns in this case, it inspired us to use a nano-erythropoietin stimulating agent (nano-ESA) made up of a nano-complex of manganese and citrate (Mn-citrate nano-complex), which has been hypothesized to have excellent antioxidant and anti-inflammatory mechanisms. Single oral dose of the nano-ESA efficiently prevented the onset of anemia as well as led to recovery from anemia in our phenylhydrazine (PHz)-intoxicated C57BL/6J mice model of anemia without any toxicological side effects. These preliminary findings may pave the way for an affordable and safe clinical use of the nano-ESA as a rapid recovery medication of anemia, especially anemia of inflammation.",

keywords = "Medical biochemistry, Molecular medicine, Nanotechnology",

author = "Monojit Das and Susmita Mondal and Ria Ghosh and Pritam Biswas and Ziad Moussa and Soumendra Darbar and Ahmed, \{Saleh A.\} and Das, \{Anjan Kumar\} and Bhattacharya, \{Siddhartha Sankar\} and Debasish Pal and Mallick, \{Asim Kumar\} and Prantar Chakrabarti and Kundu, \{Jayanta Kumar\} and Aniruddha Adhikari and Pal, \{Samir Kumar\}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = sep,

day = "16",

doi = "10.1016/j.isci.2022.105021",

language = "English",

volume = "25",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders

AU - Das, Monojit

AU - Mondal, Susmita

AU - Ghosh, Ria

AU - Biswas, Pritam

AU - Moussa, Ziad

AU - Darbar, Soumendra

AU - Ahmed, Saleh A.

AU - Das, Anjan Kumar

AU - Bhattacharya, Siddhartha Sankar

AU - Pal, Debasish

AU - Mallick, Asim Kumar

AU - Chakrabarti, Prantar

AU - Kundu, Jayanta Kumar

AU - Adhikari, Aniruddha

AU - Pal, Samir Kumar

PY - 2022/9/16

Y1 - 2022/9/16

N2 - The usual treatment for anemia and especially for anemia of inflammation (also called anemia of chronic disease) is supportive care with the target of improving the lifestyle of the patients. There is no effective medication to date for proper management. As the inflammation, erythropoiesis, and oxidative stress are the major concerns in this case, it inspired us to use a nano-erythropoietin stimulating agent (nano-ESA) made up of a nano-complex of manganese and citrate (Mn-citrate nano-complex), which has been hypothesized to have excellent antioxidant and anti-inflammatory mechanisms. Single oral dose of the nano-ESA efficiently prevented the onset of anemia as well as led to recovery from anemia in our phenylhydrazine (PHz)-intoxicated C57BL/6J mice model of anemia without any toxicological side effects. These preliminary findings may pave the way for an affordable and safe clinical use of the nano-ESA as a rapid recovery medication of anemia, especially anemia of inflammation.

AB - The usual treatment for anemia and especially for anemia of inflammation (also called anemia of chronic disease) is supportive care with the target of improving the lifestyle of the patients. There is no effective medication to date for proper management. As the inflammation, erythropoiesis, and oxidative stress are the major concerns in this case, it inspired us to use a nano-erythropoietin stimulating agent (nano-ESA) made up of a nano-complex of manganese and citrate (Mn-citrate nano-complex), which has been hypothesized to have excellent antioxidant and anti-inflammatory mechanisms. Single oral dose of the nano-ESA efficiently prevented the onset of anemia as well as led to recovery from anemia in our phenylhydrazine (PHz)-intoxicated C57BL/6J mice model of anemia without any toxicological side effects. These preliminary findings may pave the way for an affordable and safe clinical use of the nano-ESA as a rapid recovery medication of anemia, especially anemia of inflammation.

KW - Medical biochemistry

KW - Molecular medicine

KW - Nanotechnology

UR - http://www.scopus.com/inward/record.url?scp=85137414157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137414157&partnerID=8YFLogxK

U2 - 10.1016/j.isci.2022.105021

DO - 10.1016/j.isci.2022.105021

M3 - Article

AN - SCOPUS:85137414157

SN - 2589-0042

VL - 25

JO - iScience

JF - iScience

IS - 9

M1 - 105021

ER -

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this